Bayer’s venture capital unit has co-financed a $175 million investment in Affini-T Therapeutics that the company will use to expand development of T cell receptor (TCR) therapies for treatment of cancers.

The company is developing TCR therapies focused on KRAS mutations, which account for up to 30 percent of all cancers, as well as p53 mutations. The therapies have shown potential for targeting solid tumors that can be less responsive to CAR-T therapies.

Affini-T is headquarted in Boston, Mass., but also has research facilities in Seattle, Washington. The company emerged from the Fred Hutchinson Cancer Research Center in Seattle, with support from Vida Ventures, a life sciences investment firm founded in 2017 by scientists, physicians, entrepreneurs and investors.

Bayer Unit Injects $175 Million Into Affini-T Therapeutics BAYER UNIT INJECTS $175 MILLION INTO AFFINI-T THERAPEUTICS Teaser: Affini-T is headquarted in Boston, Mass., but also has research facilities in Seattle, Washington.